Citations

Clear

33 citation(s) found for "Sattar, Y".

Dose–Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression
Mohamed, Kareem A., Elshabrawi, Mohamed Nasser , Albeyoumi, Hossam , Khalil, Mohamed, AlGhazawy, Ahmed , Eshac, Youssof, Akoum, Atef , Sattar, Y, Das, Ashesh , Rahouma, Mohammed , Kumar, Akshay , Mohammed, Hossam Albeyoumi , Kumar, Akshay , Khalil, Mohamed, Eshac, Youssof , Kamal, Ibrahim

Mayo Clinic

Journal of Clinical Medicine | June 10, 2026 | Volume: 15 | Issue: 12 | Pages: 4477

10.3390/jcm15124477 | PMID 42355645 Get It

Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.
Intensive Versus Standard Systolic Blood Pressure Targets Following Successful Endovascular Thrombectomy for Acute Ischemic Stroke: A Systematic Review With Frequentist and Bayesian Meta-Analysis
Ibrahim, A, Islam, M Rafiqul , Khalil, Ibrahim , Al‐Shammari, Ali Saad , Mourad, Sohaila , Balbaa, Elsayed, Elbenawi, Hossam , Sattar, Yasar , Katsanos, Aristeidis H. , Andò, Giuseppe , Ibrahim, Ahmed , Islam, M Rafiqul , Khalil, Ibrahim , Al-Shammari, Ali Saad , Balbaa, Elsayed , Sattar, Yasar , Katsanos, Aristeidis H , Andò, Giuseppe , Manasrah, AlMothana

Mayo Clinic

Stroke: Vascular and Interventional Neurology | April 14, 2026 | Volume: 6 | Issue: 3 | Pages: No page available

10.1161/svin.125.002200 | PMID 42088319 Get It

BACKGROUND: Blood pressure management following successful reperfusion with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion remains debated. This meta-analysis aimed to determine whether intensive systolic blood pressure (SBP) management improves clinical outcomes compared with a standard approach after endovascular thrombectomy. METHODS: We systematically searched PubMed, Scopus, Embase, and Web of Science through October 2025 for relevant randomized controlled trials comparing intensive (SBP target <140 mm Hg) versus standard (SBP target <180 mm Hg) management. The primary efficacy and safety outcomes were functional independence (modified Rankin Scale score, 0–2) and any intracranial hemorrhage, respectively. We performed frequentist and Bayesian random-effects meta-analyses, supplemented by trial sequential analysis. RESULTS: Six randomized controlled trials comprising 1972 patients were included. In frequentist analysis, intensive SBP management was associated with a significantly reduced likelihood of achieving functional independence (risk ratio, 0.83 [95% CI, 0.73–0.93]). Bayesian analysis confirmed this harmful effect (posterior median risk ratio, 0.83 [95% credible interval, 0.7–1.02]), with a posterior probability of benefit of only 3.2%. Furthermore, ordinal shift analysis indicated that intensive SBP management was associated with a significant shift toward worse functional outcomes across the full modified Rankin Scale score distribution (common odds ratio, 1.26 [95% CI, 1.10–1.44]), a finding supported by a low posterior probability of benefit of 2.1%. No significant differences were observed in the risk of any intracranial hemorrhage (risk ratio, 1.05 [95% CI, 0.96–1.16]). The corresponding Bayesian analysis yielded a posterior risk ratio estimate of 1.05 (95% credible interval, 0.90–1.21) for any intracranial hemorrhage, with a posterior probability of benefit of 23%. Trial sequential analysis indicated that the cumulative evidence reached the boundary for harm and futility for the primary efficacy and safety outcomes, respectively. CONCLUSIONS: In patients with acute ischemic stroke following successful endovascular thrombectomy, intensive SBP management was associated with worse functional outcomes and provided no clear safety benefit. These findings support a standard, guideline-based SBP management strategy over an intensive approach.
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Ahmed, Muhammad , Shaikh, Narmeen, Ibrahim, Syed , Shafiq, Sabit Saad , Atta, Syed N, Naveed, Muhammad Abdullah, Sattar, Naveed, Basit, Abdul, Sattar, Naveed , Sattar, Naveed , Ibrahim, Syed , Shafqat, Shameel , Basit, Abdul , Ahmed, Muhammad

Mayo Clinic

Diabetes, Obesity and Metabolism | April 1, 2026 | Volume: 28 | Issue: 6 | Pages: 4559-4572

10.1111/dom.70714 | PMID 41918262 Get It

ABSTRACT Background Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patient‐reported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and meta‐analysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A random‐effects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoB‐2 tool. Results Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQ‐5D Index score versus placebo (MD: 0.04, p = 0.008), DTR‐QoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQ‐9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), self‐esteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion Randomised evidence suggests SGLT2 inhibitors enhance EQ‐5D Index score, diabetes‐specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
Heparin Pretreatment in ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis of Up-To-Date Evidence
Burhan, Muhammad , Virk, Hafeez Ul Hassan , Ahmed, Tarique , Daggubati, Ramesh , Burhan, Muhammad , Burhan, Muhammad , Tabassum, Shehroze , Naeem, Farhan , Qamar, Usama , Alraies, M Chadi , Sattar, Yasar

Mayo Clinic

American Journal of Therapeutics | November 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mjt.0000000000001981 | PMID 41250273 Get It

Mortality Trends in Atrial Fibrillation With Cardiomyopathy Among Patients Aged 25 and Older in the United States
Naveed, Muhammad Abdullah , Neppala, Sivaram , Ali, Ahila , Rehan, Muhammad Omer , Iqbal, Rabia , Azeem, Bazil , Ahmed, Mushood , Khan, Muhammad Zia, Agarwal, Siddharth , Chigurupati, Himaja Dutt , Shafi, Nimra , Munir, Muhammad Bilal , Azeem, Bazil , Ahmed, Mushood , Chigurupati, Himaja Dutt , Munir, Muhammad Bilal , Agarwal, Siddharth , Naveed, Muhammad Abdullah, Neppala, Sivaram , Ali, Ahila , Naveed, Hamza , Khan, Muhammad Zia , Sattar, Yasar , Asad, Zain Ul Abideen

Mayo Clinic

Pacing and Clinical Electrophysiology | October 14, 2025 | Volume: 48 | Issue: 12 | Pages: 1434-1443

10.1111/pace.70065 | PMID 41085136 Get It

ABSTRACT Background Atrial fibrillation (AF) is a prevalent arrhythmia that frequently coexists with cardiomyopathy, leading to deteriorated cardiovascular outcomes. Analyzing the trends associated with these conditions is essential for improving prevention strategies and management practices. Methods CDC WONDER (1999–2023) data were analyzed to assess AF with cardiomyopathy‐related mortality in patients aged ≥ 25. Using Joinpoint regression analysis, we calculated age‐adjusted mortality rates (AAMRs) per 100,000 patients and average annual percentage changes (AAPCs) to analyze mortality trends. Results AF with cardiomyopathy is responsible for 126,377 deaths among adults aged 25 and older. Alarmingly, AAMRs have surged from 1.8 per 100,000 in 1999 to 3.0 in 2023 (AAPC: 2.11, p < 0.001). The upward trend remains pronounced, particularly between 2016 and 2021, with an annual percentage change of 6.17 ( p = 0.02). Disparities in mortality rates are striking. Men face a higher AAMR than women (3.1 vs. 1.5), and Black individuals bear the heaviest burden at 2.4, closely followed by Whites at 2.3. Regionally, Vermont stands out with the highest AAMR at 3.6, while New York reports the lowest at 1.3. Both rural and urban areas maintain equal AAMRs of 2.1, yet the increase in rural regions is particularly concerning, reflecting an AAPC of 2.44 compared to 1.78 in urban settings. Conclusion The rising mortality rates from AF with cardiomyopathy in patients, particularly among men, Black individuals, and rural residents, demand urgent action. These concerning trends underscore a public health crisis that must be addressed.
Factors Associated With More Medication Trials Before Surgical Evaluation and Postsurgical Outcomes in Pediatric Drug-Resistant Epilepsy
Samanta, Debopam , Newell, Grace, Caraway, Avery Robert, Brock, Emily, Albert, Gregory W. , Novotny, Edward J. , Cabacar, Dewi Frances Depositario, Gaillard, William D. , Tatachar, Priyamvada , Bolton, Jeffrey , Romanowski, Erin Fedak , Alexander, Allyson , Auguste, Kurtis I. , Bernardo, Danilo , Ostendorf, Adam P. , Karia, Samir , Karakas, Cemal , Pichon, P, Olaya, Joffre , Shrey, Daniel W. , Reddy, Shilpa B. , Ganesh, Abhinaya, Hauptman, Jason S. , Singh, Rani K. , Ciliberto, Michael A. , Marashly, Ahmad , Nangia, Srishti, Arredondo, Kristen H. , Miller, D. , Sattar, Shifteh , Montenegro, Maria Augusta , Agarwal, Nitin , Galán, Fernando , Wagner, Janelle L. , Knox, Andrew , Perry, Μ. Scott , Caraway, Avery R. , Caraway, Avery Robert , Novotny, Edward J , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Gaillard, William D , Tatachar, Priyamvada , Bolton, Jeffrey Brian , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Eschbach, Krista , Alexander, Allyson L , Auguste, Kurtis I , Gonzalez-Giraldo, Ernesto , Bernardo, Danilo , Ostendorf, Adam P , Coryell, Jason , Karia, Samir , Karakas, Cemal , Javarayee, Pradeep K , Pichon, Pilar D , Shrey, Daniel W , Reddy, Shilpa B , Ganesh, Abhinaya , Hauptman, Jason , Singh, Rani K , Ciliberto, Michael A , Marashly, Ahmad , Grinspan, Zachary , Arredondo, Kristen H , Miller, Derryl J , Montenegro, Maria , Agarwal, Nitin , Galan, Fernando N , Abel, Taylor J , Knox, Andrew T , Perry, Michael Scott , Newell, Grace, Brock, Emily, Oluigbo, Chima , Wong‐Kisiel, Lily C. , McNamara, Nancy , Eschbach, Krista , Gonzalez‐Giraldo, Ernesto , Coryell, Jason , Javarayee, Pradeep , Grinspan, Zachary M. , Abel, Taylor J.

Mayo Clinic

Neurology | October 7, 2025 | Volume: 105 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214198 | PMID 41056528 Get It

Somatic mosaicism in schizophrenia brains reveals prenatal mutational processes
Maury, Eduardo A. , Jones, Attila , Seplyarskiy, Vladimir , Nguyen, Thanh Thanh L. , Rosenbluh, Chaggai , Bae, Taejong, Wang, Yifan , Abyzov, Alexej , Khoshkhoo, Sattar , Chahine, Yasmine, Zhao, Sijing , Venkatesh, Sanan , Root, Elise, Voloudakis, Georgios , Roussos, Panagiotis , Network‡, Brain Somatic Mosaicism, Brennand, Kristen , Reilly, Steven K. , Sunyaev, Shamil , Chess, Andrew , Bae, Taejeong , Moran, John V. , Zhou, Weichen , Zhu, Xiaowei , Bizzotto, Sara , Galor, Alon , Yang, Xiaoxu , Bae, Taejeong , Park, Peter J , Akbarian, Schahram , Brennand, Kristen , Reilly, Steven , Lee, Eunjung A , Sunyaev, Shamil R , Walsh, Christopher A , Chess, Andrew , Nguyen, Thanh Thanh L. , Abyzov, Alexej , Wang, Yifan , Voloudakis, Georgios , Maury, Eduardo A. , Jones, Attila , Seplyarskiy, Vladimir , Root, Elise , Network‡, Brain Somatic Mosaicism, Park, Peter J. , Akbarian, Schahram , Walsh, Christopher A.

Mayo Clinic

Science | October 10, 2024 | Volume: 386 | Issue: 6718 | Pages: 217-224

10.1126/science.adq1456 | PMID 39388546 Get It

Germline mutations modulate the risk of developing schizophrenia (SCZ). Much less is known about the role of mosaic somatic mutations in the context of SCZ. Deep (239×) whole-genome sequencing (WGS) of brain neurons from 61 SCZ cases and 25 controls postmortem identified mutations occurring during prenatal neurogenesis. SCZ cases showed increased somatic variants in open chromatin, with increased mosaic CpG transversions (CpG>GpG) and T>G mutations at transcription factor binding sites (TFBSs) overlapping open chromatin, a result not seen in controls. Some of these variants alter gene expression, including SCZ risk genes and genes involved in neurodevelopment. Although these mutational processes can reflect a difference in factors indirectly involved in disease, increased somatic mutations at developmental TFBSs could also potentially contribute to SCZ.
Impact of frailty in hospitalized patients undergoing catheter ablation for atrial fibrillation
Ali, Shafaqat , Khlidj, Yehya , Hendricks, Emily , Farooq, Faryal , Alruwaili, Waleed , Keisham, Bijeta , Gonuguntla, Karthik , Sattar, Yasar , Shaik, Ayesha , Brar, Vijaywant , Sorajja, Dan , Dominic, Paari , Helmy, Tarek , Khlidj, Yehya , Sattar, Yasar , Shaik, Ayesha , Dominic, Paari , Kumar, Manoj , Duhan, Sanchit , Asad, Zain Ul Abideen

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 30, 2024 | Volume: 35 | Issue: 10 | Pages: 1929-1938

10.1111/jce.16383 | PMID 39075813 Get It

Abstract Background Catheter Ablation (CA) is an effective treatment for atrial fibrillation (AF). However, frail elderly patients have been understudied due to their exclusion from landmark trials. Objectives Our study aims to evaluate outcomes in this population. Methods The national readmission database (2016–2020) was queried, and frailty categories were defined based on hospital risk frailty scores ≦5 as low while >5 as intermediate/high frailty (IHF). We used multivariate regression and propensity‐matched analysis to compare outcomes in patients undergoing CA for atrial fibrillation based on frailty index. Results Among 55 936 CAs for AF, 33,248 patients had low frailty, while 22 688 had intermediate/high frailty (IHF). After propensity matching (N 12 448), IHF patients were found to have higher adverse events, including mortality (3% vs. 0.3%, p < .001), stroke (1.9% vs. 0.2%, p < .001), acute heart failure (53.8% vs. 42.2%, p < .001), AKI (42.5% vs. 6.8%, p < .001), pericardial complications (2.8 vs. 1.6%, p < .001), respiratory complications (27.8 vs. 7.2%, p < .001), major adverse cardiovascular events (21.2 vs. 9.4%, p < .001) and net adverse events (76.7 vs. 55%, p < .001). IHF patients had higher readmissions at 30 (15.5 vs. 12.6%, p < .001), 90 (31.9 vs. 25.1%, p < .001), and 180‐day (41 vs. 34.7%, p < .001) intervals. A higher median length of stay (LOS) (7 vs. 3 days, p < .001) and cost ($44 287 vs. $27 517, p < .001) at index admission and subsequent readmissions were also observed ( p < .001). Conclusion Intermediate/high frailty patients undergoing catheter ablation had worse clinical outcomes, higher healthcare burden, and readmission rates. LOS has decreased in both groups from 2016 to 2020; however, total cost has increased.